University of Texas MD Anderson Cancer Center
Department Of Experimental Therapeutics,
United States
Research Article
Systematic Review of Monitoring Criteria to Interpret CA125 Increments during First-Line Chemotherapy and the Subsequent Follow-Up Period among Patients with Advanced Epithelial Ovarian Cancer
Author(s): Suher Othman Abu Hassan*, Dorte L Nielsen, Malgorzata K Tuxen, Robert C Bast Jr and Gyorgy SoletormosSuher Othman Abu Hassan*, Dorte L Nielsen, Malgorzata K Tuxen, Robert C Bast Jr and Gyorgy Soletormos
Background: Optimal clinical management of ovarian cancer patients requires prompt and accurate determination of whether primary or recurrent disease is responding to chemotherapy. If CA125 is to fill this need, we must understand the design and outcomes of clinical trials that have established a correlation between CA125 levels and growth or shrinkage of tumor burden. It is particularly important to define the magnitude of changes in CA125 concentrations that indicate cancer growth and prompt cessation of ineffective therapy. Objective: To review clinical trials which test the ability of CA125 to monitor ovarian cancer growth during chemotherapy for primary disease and detection of recurrence. Methods: The Medline and Embase databases were searched for original articles published in English between January 1982 and May 2014 that evaluated the utility of CA125 for monitoring ovarian c.. Read More»
Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 